We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genome-Wide Mutation-Searching Computational Software Designed for Genomic Medicine

By LabMedica International staff writers
Posted on 31 Aug 2014
Analysis software cross-references a patient’s symptoms with his genome sequence to help physicians in the diagnosis of disease. More...


This software was created by a team of scientists from A*STAR’s Genome Institute of Singapore (GIS), led by Dr. Pauline Ng. The research findings were published August 3, 2014, in the journal Nature Methods. Phen-Gen software can identify defective genes responsible for diseases by up to 88%, generating results in 15 to 30 minutes. It has been shown to be faster and more efficient compared to current technology analyzing genomes for this purpose.

One field that Dr. Ng is currently working on is integrating the Phen-Gen technique in the diagnosis of rare diseases. Rare diseases are frequently difficult to diagnose based on symptoms alone. By using Phen-Gen, doctors are able to make a more accurate diagnosis based on a patient’s distinctive genetic code.

Dr. Ng’s team is working with doctors in local and international hospitals to incorporate Phen-Gen to diagnose patients with rare disorders. “We aim to translate scientific research to help people directly,” said senior author Dr. Ng. “To this end, GIS has created a program to help diagnose patients with rare disorders. Phen-Gen works with both exome and whole genome sequencing data. It is the first algorithm to leverage disease symptoms and give genome-wide predictions.”

Most rare diseases, such as those that affect cardiac, neurologic, or brain development, manifest early in life. “There is little else more satisfying than the opportunity to help a sick patient, and through our research at GIS, we want others in the world to benefit as well,” said first author Dr. Asif Javed. “The program is also downloadable online for those who prefer to keep their DNA information private.”

The executive director of the GIS, Prof. Ng Huck Hui, commented, “As we enter the genomics era with more powerful next-generation sequencing technologies that can analyze the human genomes at a reduced cost, data analytics becomes a bottleneck. Dr. Pauline Ng’s group has taken on this exciting challenge to develop analytics capabilities. In partnership with the Singapore hospitals, the GIS has initiated a research project on sequencing patients with undiagnosed conditions or congenital disorders. The Phen-Gen method is timely as it fills an urgent gap in hospitals for accurate diagnosis of rare diseases.”

Related Links:

A*STAR’s Genome Institute of Singapore 
Phen-Gen software




New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.